G. de Castro Jr Et Al. , "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11, pp.1986-1991, 2023
de Castro Jr, G. Et Al. 2023. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11 , 1986-1991.
de Castro Jr, G., Kudaba, I., Wu, Y., Lopes, G., Kowalski, D. M., TURNA, Z. H., ... Caglevic, C.(2023). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study. JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11, 1986-1991.
de Castro Jr, Gilberto Et Al. "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study," JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11, 1986-1991, 2023
de Castro Jr, Gilberto d. Et Al. "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11, pp.1986-1991, 2023
de Castro Jr, G. Et Al. (2023) . "Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study." JOURNAL OF CLINICAL ONCOLOGY , vol.41, no.11, pp.1986-1991.
@article{article, author={Gilberto de Castro Jr Et Al. }, title={Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score=1% in the KEYNOTE-042 Study}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2023, pages={1986-1991} }